Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)

Pharmacogenomics Journal

Volumn 5, Issue 2, 2005, Pages 135-141

  Barrero, F J ^a   Ampuero, I ^b   Morales, Blas ^a   Vives, F ^c   de Dios Luna del Castillo, J ^c   Hoenicka, J ^b   Garcia Yebenes J ^b,d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Jimenez Diaz Foundation   (Spain)

Author keywords

Cannabinoid system; CNR1; Depression; Parkinson's disease; Polymorphisms

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; CANNABINOID; CANNABINOID 1 RECEPTOR; DNA; GLUTAMIC ACID; MONOAMINE; TYROSINE;

ADULT; AGED; AKINESIA; ALLELE; ARTICLE; BEHAVIOR; BRAIN FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE COURSE; DNA DETERMINATION; EMOTION; FEMALE; FISHER EXACT TEST; GENETIC ASSOCIATION; GENETIC CODE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; OSTEOARTHRITIS; PARKINSON DISEASE; PATHOGENESIS; PATIENT CARE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; RISK FACTOR; SAMPLE SIZE; STATISTICAL ANALYSIS; SYMPTOM; TREMOR; TRINUCLEOTIDE REPEAT;

AGED; CELL ADHESION MOLECULES, NEURONAL; DEPRESSIVE DISORDER; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROPEPTIDES; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, CELL SURFACE; SEX CHARACTERISTICS; TRINUCLEOTIDE REPEATS;

MARTES PENNANTI;

EID: 16344376222     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500301     Document Type: Article

References (59)

1. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996; 14: 317-335.
2. Gibb WRG, Lees AJ. Pathological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S (eds). Movement Disorders vol. 3. Butterworth-Heinemann: Oxford, 1994, pp 146-166.
3. Chia LG, Cheng LJ, Chuo LJ, Cheng FC, Cu JS. Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. J Neurol Sci 1995; 133: 73-78.
4. Cummings LF. Depression and Parkinson's disease: a review. Am J Psychiatric 1992; 149: 443-454.
5. Tandberg E, Larsen JP, Arsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53: 175-179.
6. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363-375.
7. Serrano-Dueñas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease. Rev Neurol 2002; 35: 1010-1014.
8. Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265-1267.
9. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression intellectual impairment and Parkinson's disease. Neurology 1981; 31: 645-650.
10. Mayeux R. Behavioral manifestations of movement disorders. Neurol Clin 1984; 2: 527-540.
11. Huber SJ, Paulson GW, Shuttleworth EC. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 51: 855-858.
12. Liu C-Y, Wang S-J, Fuh J-L, Liu CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson's disease. J Neurol 1997; 244: 493-498.
13. Gil Saladié D, Delgado González M. y cols. La depresión de la enfermedad de Parkinson y su relación con las manifestaciones cognitivas y motoras. Neurología 1992; 7: 176-179.
14. Hammond-Tooke G, Pollock M. Depression, dementia, and Parkinson's disease. In: Hoseph AB, Young RR (eds). Movement Disorders in Neurology and Neuropsychiatry, 2 edn. Blackwell Science: Massachusetts, 1999, pp 195-204.
15. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY (eds). Psychopharmacology: The Third Generation of Progress. Raven Press: New York, 1987, pp 513-526.
16. Howlett AC, Bidaut-Rusell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioural characterization. Trends Neurosci 1990; 13: 420-423.
17. Tsout K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistachemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
18. Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES et al. Genetic and physical mapping of the human cannabinoid receptor gene chromosome 6q14-ql5. New Biol 1991; 3: 880-885.
19. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279: 129-134.
20. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451-460.
21. Sieradzan KA, Fox SH, Hill M, Disck JP, Crossman AR, Brotchie JM et al. Cannabinoids reduce levodopa-incluced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57: 2108-2111.
22. Sañudo-Peña MC, Tsoy K, Walker JM. Motor action of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 713.
23. Lastres-Becker I, Cebeira M, de Cevallos M, Zeng B-Y, Jenner P, Ramos JA. Fernández-Ruiz increased cannabinoid CB1 receptor binding and activation of GPT-binding proteins in the basal ganglia of patients with Parkinson's disease and MPTP-treated marmosets. Eur J Neurosci 2001; 14: 1827-1832.
24. Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R. Cannabis associated psychosis with hipomanic features. Lancet 1982; 2: 1364-1366.
25. Devane AA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
26. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327: 535-550.
27. Banerjee SP, Synder SH, Mechulam R. Cannabinoids: L influence on neurotransmitter uptake in rat brain synaphosomes. J Pharmacol Exp Ther 1975; 194: 74-81.
28. Musty RE, Kaback L. Relationships between motivation and depression in chronic marijuana users, Life Sci 1995; 56: 2151-2158.
29. Mato S, Rodriguez-Puertas R, González-Maeso J, Meana J, Sallés J, Pazos A. Receptores centrales para cannabinoides en cerebro humano postmortem: estudio radiométrico en la depresión mayor. l a Reunión nacional sobre investigación en cannabinoides, Madrid, 2000.
30. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99: 8384-8388.
31. Wainwright NWJ, Surtees PG. Childhood adversity, gender and depression over the life-course. J Affect Disorders 2002; 72: 33-44.
32. Martin M, Ledent C, Parmentir M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379-387.
33. Dawson E. Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiat Genet 1995; 5: 550.
34. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
35. Mizuno Y, Hattori N, Mori H, Suzuki T, Tanaka K. Parkin and Parkinson's disease. Curr Opin Neurol 2001; 14: 477-482.
36. Vaughan JR, Davis MB, Wood NW. Genetics of Parkinsonism: a review. Ann Hum Genet 2001; 65: 111-126.
37. Tan EK, Khajavi M, Thornby JL, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533-538.
38. Schroth GP, Chou PJ, Ho PS. Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. J Biol Chem 1992; 267: 11846-11855.
39. Comings DE. Polygenic inheritance and minisatellites. Psychiat Genet 1996; 6: 157-158.
40. Tsai SJ, Wang YC, Hong CJ. Association study between cannabonoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. Am J Med Genet 2001; 105: 219-221.
41. Comings DE, Muhleman D, Gade R, Jonson P, Verde R, Saucier G et al. Cannabinoid receptor gene (CNR1): association with IV drug abuse. Mol Psychiatry 1997; 2: 161-168.
42. Lutz G, Schmidt T, Samochowiec J, Finckh U, Fiser-Piosik E, Horodinicki J et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depen 2002; 65: 221-224.
43. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515-518.
44. Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drugs users. Addict Biol 2001; 6: 183-187.
45. Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000; 5: 128-130.
46. 35S] GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004; 9: 184-190.
47. Melamed E. Neurobehavioral abnormalities in Parkinson's disease. In: Watt RL, Koller WC (eds). Movement Disorders. Neurologic Principles and Practice. McGraw-Hill: New York, 1997, pp 257-261.
48. Errea-Abad JM, Ara-Callizo JR, Aibar-Remón C. Drug-induced Parkinsonism. Clinical aspects compared with Parkinson disease. Rev Neurol 1998; 27: 35-39.
49. Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65: 49-60.
50. Hantz P, Caradoc-Davis G, Caradoc-Davis T, Weatherall M, Dixon G. Depression in Parkinson's disease. Am J Psychiatry 1994; 151: 1010-1014.
51. Santamaría J, Tolosa E, Valles A. A Parkinson's disease with depression: a possible subgroup of idiopathic Parkinsonism. Neurology 1986; 36: 1130-1133.
52. Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, Merello M et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 1998; 13: 29-33.
53. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment and Parkinson's disease. Neurology 1991; 31: 645-650.
54. Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-Jimenez R et al. Association between the cannabinoid receptor gene (CNR1) and childhood attention-deficit/hyperactivity disorder in Spanish male alcoholic, patients. Mol Psychiatry 2003; 8: 466-467.
55. Macritchie KA, Young AH. Emerging targets for the treatment of depressive disorder. Expert Opin Ther targets 2001; 5: 601-612.
56. Gelb DJ, Oliver E, Gliman S. Diagnostic criteria for Parkinson Disease. Arch Neurol 1999; 56: 33-39.
57. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
58. Fahn S, Elton RL. Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). Recent Developments in Parkinson's Disease, vol. 2. Macmillan Healthcare information: Florham Park, NJ, 1987, pp 153-163, 293-304.
59. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.